XML 33 R21.htm IDEA: XBRL DOCUMENT v3.21.2
MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES - (Tables)
 6 Months Ended
Jun. 30, 2021
Novartis Institutes for BioMedical Research, Inc.  
Research and Development Arrangement, Contract to Perform for Others [Line Items]  
Revenues Recognized under Agreement Revenues recognized under the agreement were as follows (in thousands):
Three Months Ended
June 30,		Six Months Ended
June 30,
2021202020212020
Revenue related to Novartis agreement:
Recognition of upfront license fee$7,559 $— $13,759 $— 
Research services2,022 — 3,683 — 
Total$9,581 $— $17,442 $— 
Biogen MA, Inc.  
Research and Development Arrangement, Contract to Perform for Others [Line Items]  
Revenues Recognized under Agreement
Revenues recognized under the agreement were as follows (in thousands):
Three Months Ended
June 30,		Six Months Ended
June 30,
2021202020212020
Revenue related to Biogen agreement:
Recognition of license and stand-ready fee$7,306 $6,744 $14,612 $6,744 
Research services3,461 1,434 6,605 1,434 
Total$10,767 $8,178 $21,217 $8,178 
Kite Pharma, Inc.  
Research and Development Arrangement, Contract to Perform for Others [Line Items]  
Revenues Recognized under Agreement Revenues recognized under the agreement were as follows (in thousands):
Three Months Ended
June 30,		Six Months Ended
June 30,
2021202020212020
Revenue related to Kite agreement:
Recognition of license and stand-ready fee$6,227 $6,227 $12,386 $12,454 
Research services97 1,195 226 2,187 
Total$6,324 $7,422 $12,612 $14,641 
Sanofi Genzyme  
Research and Development Arrangement, Contract to Perform for Others [Line Items]  
Revenues Recognized under Agreement Revenues recognized under the agreement were as follows (in thousands):
Three Months Ended
June 30,		Six Months Ended
June 30,
2021202020212020
Revenue related to Sanofi agreement:
Recognition of upfront fee$206 $380 $433 $(349)
Research services613 1,155 1,292 2,875 
Milestone achievement138 257 292 (235)
Total$957 $1,792 $2,017 $2,291